Search for: "Shire Pharmaceutical Development Inc"
Results 21 - 34
of 34
Sort by Relevance
|
Sort by Date
14 Jul 2010, 6:47 pm
(Patent Docs) Lialda (Mesalazine /Mesalamine) – US: Patent infringement complaint following Paragraph IV certification: Shire Development Inc. et al. v. [read post]
11 Jul 2010, 9:52 pm
Shire Development Inc. et al. v. [read post]
10 Jun 2010, 3:58 am
Par Pharmaceutical, Inc. [read post]
5 May 2010, 4:46 am
Cyclacel Pharmaceuticals Inc. [read post]
27 Apr 2010, 10:58 pm
Solstice International Partners et al (Docket Report) US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog) Products Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs) Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix patent, based on Mylan’s… [read post]
29 Mar 2010, 5:00 am
Shire, Inc., 2010 WL 937279 (Pa. [read post]
2 Feb 2010, 11:25 am
Those who took the time and made the effort to nominate their personal recommendations for Blawg Review of the Year 2009 know how daunting a task it is to single out a half dozen outstanding presentations of Blawg Review in 2009. [read post]
2 Feb 2010, 11:25 am
Those who took the time and made the effort to nominate their personal recommendations for Blawg Review of the Year 2009 know how daunting a task it is to single out a half dozen outstanding presentations of Blawg Review in 2009. [read post]
17 Aug 2009, 8:01 am
As a result, the giant generic pharmaceutical concern has become the utmost patent copycat pharmaceutical player on the international scene. [read post]
17 Aug 2009, 8:01 am
As a result, the giant generic pharmaceutical concern has become the utmost patent copycat pharmaceutical player on the international scene. [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ that its… [read post]
11 Jul 2008, 4:30 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on… [read post]
4 Apr 2008, 1:00 am
: (IPBiz) Pharma & Biotech - Products Abilify (Aripiprazole) – Otsuka files US patent infringement suit against Teva over seeking approval for generic Abilify: (IP Law360), Aricept (Donepezil) – US federal judge grants Eisai’s request for preliminary injunction blocking Teva from marketing generic version of Aricept: (IP Law360), (Orange Book Blog), Carbatrol (Carbamazepine) – US federal judge delivers mixed ruling in Shire… [read post]
